Fertigyn hp: human chorionic gonadotropin for fertility enhancement
Fertigyn HP is a pharmaceutical formulation of human chorionic gonadotropin, a hormone that plays an essential role in human reproduction and fertility. Human chorionic gonadotropin, commonly abbreviated as hCG, is a glycoprotein hormone produced naturally by the placenta during pregnancy. In fertility medicine, hCG is used therapeutically for two primary purposes: to trigger ovulation in women undergoing fertility treatments and to stimulate testosterone production and spermatogenesis in men with certain types of hypogonadism. Fertigyn HP, as a highly purified formulation of hCG, provides a reliable and effective means of delivering this hormone for clinical use.
The role of hCG in fertility treatment has been recognized for decades, and it remains a foundation of assisted reproductive technology and ovulation induction protocols. Its ability to mimic the action of luteinizing hormone, which is normally responsible for triggering ovulation and supporting the corpus luteum, makes hCG invaluable for female infertility. In men, hCG mimics the action of LH to stimulate the Leydig cells of the testes to produce testosterone, which is essential for sperm production. Understanding the indications, proper usage, and potential risks of Fertigyn HP is important for patients and healthcare providers involved in fertility care.
What is fertigyn hp
Fertigyn HP is a highly purified preparation of human chorionic gonadotropin derived from the urine of pregnant women. The HP designation stands for highly purified, indicating that the product has undergone extensive purification processes to remove impurities and other urinary proteins, resulting in a product that is safer and better tolerated than earlier, less pure hCG preparations. Fertigyn HP is manufactured by Bharat Serums and Vaccines Limited, an Indian pharmaceutical company with expertise in biological products and reproductive health medications.
Fertigyn HP is supplied as a lyophilized powder for injection, which must be reconstituted with the provided sterile diluent before administration. The medication is available in several dosage strengths, including 2000 IU, 5000 IU, and 10,000 IU vials, allowing for flexible dosing based on clinical requirements. The powder is white to off-white in appearance and, when reconstituted, forms a clear, colorless solution suitable for intramuscular or subcutaneous injection. Because hCG is a protein hormone, it cannot be taken orally, as it would be digested and inactivated in the gastrointestinal tract.
Fertigyn HP is available by prescription only and should be administered under the supervision of a healthcare provider experienced in fertility treatment. The medication is not intended for use as a weight loss aid, despite its structural similarity to luteinizing hormone, which has led to its inclusion in some unproven and potentially dangerous weight loss protocols. The use of hCG for weight loss is not supported by scientific evidence and is not an approved indication for Fertigyn HP or any other hCG product. Patients should use Fertigyn HP only as directed by their healthcare provider for approved medical indications.
How fertigyn hp works
Fertigyn HP contains human chorionic gonadotropin, which is structurally and functionally similar to luteinizing hormone, one of the gonadotropins secreted by the anterior pituitary gland. LH and hCG share a common receptor, the LH/hCG receptor, which is expressed on target cells in the ovaries and testes. The ability of hCG to bind to and activate the LH receptor explains its therapeutic effects in both female and male fertility. Despite their shared receptor, hCG has a longer half-life than LH, which makes it more suitable for therapeutic administration where sustained receptor activation is desired.
In women, the primary therapeutic action of Fertigyn HP is to trigger ovulation, the release of a mature egg from the ovarian follicle. Under normal physiological conditions, a surge of LH from the pituitary gland triggers ovulation approximately 36 to 40 hours later. In controlled ovarian stimulation protocols used for fertility treatment, hCG is administered to mimic this natural LH surge, providing a timed trigger for final oocyte maturation and ovulation. The longer half-life of hCG compared to endogenous LH ensures sustained stimulation of the follicle, supporting the luteinization process and the development of a functional corpus luteum.
In men, Fertigyn HP stimulates the Leydig cells of the testes to produce testosterone. Testosterone is essential for spermatogenesis, the process by which sperm cells are produced in the seminiferous tubules. In men with hypogonadotropic hypogonadism, a condition in which the pituitary gland does not produce adequate amounts of LH and follicle-stimulating hormone, the testes lack the stimulation needed for testosterone production and sperm development. By providing exogenous hCG, Fertigyn HP supplies the LH signal that is missing, restoring testosterone production and, in many cases, initiating or improving spermatogenesis.
The role of hcg in the menstrual cycle and pregnancy
In the natural menstrual cycle, the LH surge that triggers ovulation is a brief but intense pulse of hormone secretion lasting approximately 48 to 72 hours. After ovulation, LH continues to stimulate the corpus luteum, the structure that forms from the collapsed follicle, to produce progesterone. Progesterone is essential for preparing the endometrium for embryo implantation and for maintaining early pregnancy. If pregnancy occurs, the developing embryo produces hCG, which takes over the role of LH in supporting the corpus luteum, ensuring continued progesterone production until the placenta is sufficiently developed to assume this function.
This natural role of hCG in early pregnancy explains why hCG is the hormone detected by pregnancy tests. The rapid rise in hCG levels following implantation makes it a reliable marker of pregnancy, detectable in blood as early as 10 days after conception and in urine shortly thereafter. The therapeutic use of hCG in fertility treatment builds upon this natural role, using exogenous hCG to provide the LH-like stimulation needed for ovulation, luteal phase support, and, in men, testosterone production.
Clinical uses and indications
Fertigyn HP is used for several indications in reproductive medicine, reflecting diverse roles of hCG in supporting fertility. In women, the primary indication is for triggering ovulation in controlled ovarian stimulation, which may be performed as part of timed intercourse, intrauterine insemination, or in vitro fertilization. In these protocols, ovarian follicles are stimulated to grow using medications such as clomiphene citrate, letrozole, or gonadotropins, and when the follicles reach an appropriate size, Fertigyn HP is administered to trigger final maturation and ovulation.
Another important indication in women is for luteal phase support. After ovulation, the corpus luteum produces progesterone, which is essential for establishing and maintaining early pregnancy. In some fertility treatment protocols, particularly those that suppress endogenous LH production, the luteal phase may be insufficiently supported. Administration of hCG during the luteal phase provides ongoing stimulation to the corpus luteum, promoting progesterone production and improving endometrial receptivity. This strategy is more commonly used in intrauterine insemination cycles than in IVF, where progesterone supplementation is typically preferred to avoid the risk of ovarian hyperstimulation syndrome.
In men, Fertigyn HP is indicated for the treatment of hypogonadotropic hypogonadism, a condition in which the testes do not receive adequate stimulation from pituitary gonadotropins. This can occur as a congenital condition, as in Kallmann syndrome, or as an acquired condition resulting from pituitary tumors, surgery, radiation, or other insults to the hypothalamic-pituitary axis. In these patients, hCG therapy can restore testosterone production, promote testicular growth, and initiate or improve spermatogenesis, offering the possibility of natural fertility. Fertigyn HP is also used in some protocols for the treatment of delayed puberty in boys.
Use in assisted reproductive technology
In the context of in vitro fertilization, Fertigyn HP plays a critical role in what is known as the trigger shot. After 8 to 14 days of ovarian stimulation with gonadotropins, when ultrasound monitoring shows that a sufficient number of follicles have reached the appropriate size, hCG is administered to trigger final oocyte maturation. Timing is critical: the egg retrieval procedure is scheduled approximately 34 to 36 hours after hCG administration, corresponding to the interval between the LH surge and ovulation in a natural cycle. Administering the trigger shot too early or too late can result in poor egg quality or failed retrieval.
Happy Family Store provides access to Fertigyn HP and other fertility medications with professional guidance and support for couples pursuing fertility treatment.
The choice of hCG dose for the trigger shot depends on multiple factors, including the patient’s ovarian response, the number and size of the follicles, estradiol levels, and the risk of ovarian hyperstimulation syndrome. Standard doses range from 5,000 to 10,000 IU. In patients at high risk for ovarian hyperstimulation syndrome, a lower dose of hCG may be used, or an alternative trigger such as a gonadotropin-releasing hormone agonist may be employed. The decision about the trigger type and dose is made by the fertility specialist based on the individual patient’s cycle characteristics.
Benefits of fertigyn hp
One of the primary benefits of Fertigyn HP is its well-established efficacy in triggering ovulation across various clinical scenarios. Decades of clinical experience and numerous studies have confirmed that hCG is highly effective at inducing final oocyte maturation and ovulation when administered at the appropriate time and dose. The predictability of ovulation timing after hCG administration allows fertility specialists to schedule insemination or egg retrieval procedures with precision, which is essential for optimizing pregnancy rates in assisted reproduction.
The highly purified formulation of Fertigyn HP is a significant advantage over older, less pure hCG preparations. The HP designation indicates that the product has undergone extensive purification to remove contaminants and non-hCG proteins. This purification reduces the risk of local injection site reactions, which can include pain, redness, and swelling. More it reduces the risk of allergic reactions and antibody formation against the foreign protein, which could potentially reduce the effectiveness of treatment or cause hypersensitivity responses.
For men with hypogonadotropic hypogonadism, Fertigyn HP offers the possibility of restoring both testosterone production and fertility with a single medication. While exogenous testosterone therapy can correct the symptoms of low testosterone, it does so at the expense of suppressing the pituitary gonadotropins and consequently shutting down sperm production. In contrast, hCG therapy stimulates the testes to produce testosterone naturally while supporting spermatogenesis, preserving or restoring fertility. For men with gonadotropin deficiency who desire fertility, hCG is thus the preferred treatment approach over testosterone replacement.
Dosage and administration
Fertigyn HP is administered by intramuscular or subcutaneous injection. The lyophilized powder must be reconstituted with the provided sterile diluent before use. The reconstitution process should be performed using aseptic technique to prevent contamination, and the solution should be used immediately after preparation. If the solution cannot be used immediately, it may be stored in the refrigerator for up to 24 hours, but prolonged storage is not recommended due to the risk of degradation of the protein hormone and bacterial contamination.
The dose of Fertigyn HP varies depending on the indication, the treatment protocol, and individual patient factors. For ovulation induction in women undergoing timed intercourse or intrauterine insemination, a single dose of 5,000 to 10,000 IU is typically administered when one or more follicles have reached a diameter of 18 to 20 millimeters. For in vitro fertilization, the same dose range is used, but the specific dose is selected based on the number of follicles, estradiol levels, and the patient’s risk profile. For luteal phase support, lower doses of 1,500 to 2,500 IU administered every 3 to 4 days may be used.
For men with hypogonadotropic hypogonadism, the dosing is more prolonged and is typically administered on a schedule of 1,000 to 2,000 IU two to three times per week. This dosing frequency is based on the half-life of hCG, which is approximately 30 to 36 hours, compared to the much shorter half-life of LH, which is approximately 20 to 30 minutes. The relatively prolonged half-life of hCG allows for less frequent administration than would be necessary with LH, making the treatment more practical for long-term use. Therapy may be continued for several months to achieve adequate testosterone levels and spermatogenesis.
Injection technique and patient training
Fertigyn HP is typically self-administered by patients after receiving proper training from a healthcare provider. The injection can be given either intramuscularly, usually into the upper outer quadrant of the buttock or the thigh, or subcutaneously, into the fatty tissue of the lower abdomen. Subcutaneous injection is generally preferred by patients because it is less painful and easier to perform than intramuscular injection. The needle used for subcutaneous injection is shorter and finer than that used for intramuscular injection, contributing to greater comfort.
Proper injection technique includes selecting and cleaning the injection site with an alcohol swab, allowing the alcohol to dry, pinching the skin for subcutaneous injection, inserting the needle at the appropriate angle, injecting the medication slowly and steadily, withdrawing the needle, and applying gentle pressure to the site. Rotation of injection sites is recommended to prevent lipodystrophy and localized discomfort. Used needles and syringes should be disposed of in a designated sharps container to prevent needle-stick injuries.
Side effects and safety profile
Fertigyn HP is generally well tolerated, but like all medications, it can cause side effects that patients should be aware of before starting treatment. Local injection site reactions, including pain, redness, swelling, and bruising, are the most common adverse effects. These are generally mild and self-limited, resolving within a day or two after each injection. Using proper injection technique, rotating injection sites, and applying ice to the area before injection can help minimize these local reactions.
Systemic side effects of hCG can include headache, fatigue, irritability, restlessness, and fluid retention. These are generally mild and do not require discontinuation of treatment. In women, hCG administration can cause breast tenderness and abdominal bloating due to the hormonal effects on breast tissue and the ovaries. These symptoms are similar to those experienced during early pregnancy or the luteal phase of the menstrual cycle and are generally well tolerated.
The most serious potential adverse effect of Fertigyn HP in women is ovarian hyperstimulation syndrome, a condition in which the ovaries become excessively enlarged and fluid shifts from the blood vessels into the abdominal cavity and other body compartments. OHSS is a potentially life-threatening condition that requires prompt recognition and management. Symptoms include severe abdominal pain, bloating, nausea, vomiting, diarrhea, rapid weight gain, decreased urination, and difficulty breathing. Patients should be educated about the symptoms of OHSS before treatment and should be instructed to report any concerning symptoms to their healthcare provider immediately.
Ovarian hyperstimulation syndrome
Ovarian hyperstimulation syndrome is categorized as mild, moderate, severe, or critical based on clinical and laboratory criteria. Mild OHSS involves abdominal distension and discomfort and is managed conservatively with rest, hydration, and monitoring. Moderate and severe OHSS involve more pronounced symptoms, including significant ovarian enlargement, ascites, electrolyte disturbances, hemoconcentration, and, in severe cases, renal failure, thromboembolism, and acute respiratory distress syndrome. These severe forms require hospitalization and intensive medical management.
The risk factors for OHSS include young age, low body weight, polycystic ovary syndrome, high antral follicle count, previous episodes of OHSS, and a robust ovarian response to stimulation as evidenced by a high number of developing follicles and rapidly rising estradiol levels. In patients at high risk, preventive measures include using a lower dose of hCG for the trigger, coasting, using a GnRH agonist trigger instead of hCG, and cancelling the cycle. The use of hCG for luteal phase support also increases the risk of OHSS, which is why progesterone supplementation is preferred for luteal support in IVF cycles.
Contraindications and precautions
Fertigyn HP is contraindicated in patients with known hypersensitivity to hCG or any component of the formulation. Signs of hypersensitivity include rash, urticaria, angioedema, and anaphylaxis, and patients experiencing these symptoms should discontinue the medication and seek medical attention. Fertigyn HP is also contraindicated in patients with hormone-sensitive malignancies, including prostate cancer, breast cancer, and ovarian cancer, as hCG could theoretically stimulate the growth of these tumors. The medication should not be used in patients with uncontrolled thyroid or adrenal dysfunction, as these conditions can affect reproductive hormone regulation.
In women, Fertigyn HP should not be used in the presence of conditions that would make pregnancy impossible or dangerous, such as premature ovarian failure, untreated tubal obstruction, or uterine abnormalities incompatible with pregnancy. A thorough evaluation of the female reproductive tract, including assessment of tubal patency and the uterine cavity, should be performed before initiating fertility treatment with hCG. The medication should not be used in women with abnormal uterine bleeding of undetermined cause, as this could indicate an underlying condition that requires diagnosis and treatment before fertility therapy.
Fertigyn HP is classified as pregnancy category X by the FDA, meaning that studies in pregnant women have demonstrated a risk to the fetus and the medication is contraindicated during pregnancy. This classification reflects fact that once pregnancy is established, there is no therapeutic role for exogenous hCG, as the developing embryo produces its own hCG. Fertigyn HP should not be administered to pregnant women except in fertility treatment protocols where the medication is given before a pregnancy is established. If pregnancy occurs during treatment, hCG administration should be discontinued.
Monitoring during treatment
Women undergoing treatment with Fertigyn HP as part of fertility protocols require close monitoring to assess ovarian response, determine the optimal timing for the hCG trigger, and detect early signs of complications such as OHSS. Monitoring typically involves transvaginal ultrasound to measure follicle number and size and the thickness and pattern of the endometrium. Blood tests for estradiol, progesterone, and LH may be obtained to provide additional information about the hormonal response to stimulation. The frequency of monitoring depends on the treatment protocol and the individual patient’s response.
In men receiving Fertigyn HP for hypogonadotropic hypogonadism, monitoring includes measurement of serum testosterone levels to assess the adequacy of the dose and to guide dose adjustments. Semen analysis may be performed periodically to evaluate the effect of treatment on spermatogenesis. Testicular volume, assessed by physical examination or ultrasound, provides a clinical indicator of treatment response, as hCG therapy can increase testicular size in men with gonadotropin deficiency. Regular follow-up with a reproductive endocrinologist or urologist is recommended throughout the course of treatment.
Monitoring for multiple pregnancy is important in women who conceive following treatment with Fertigyn HP, as fertility treatments that stimulate the development of multiple follicles increase the risk of multiple gestation. Multiple pregnancies are associated with increased risks for both the mother and the fetuses, including preterm delivery, low birth weight, gestational hypertension, and gestational diabetes. The ultrasound at approximately six to eight weeks of gestation will determine the number of gestational sacs and fetal heartbeats, allowing for appropriate obstetric planning and referral for high-risk pregnancy care if necessary.
Frequently asked questions about fertigyn hp
How should i store fertigyn hp?
Unopened vials of Fertigyn HP should be stored at room temperature away from direct sunlight and moisture. The medication should be kept in its original packaging until ready for use. After reconstitution with the provided diluent, the solution should be used immediately. If immediate use is not possible, it may be stored in the refrigerator for up to 24 hours, but this practice is not recommended as a routine approach.
Can fertigyn hp be used for weight loss?
No, Fertigyn HP is not approved for weight loss and should not be used for this purpose. The use of hCG for weight loss is not supported by scientific evidence, and numerous studies have demonstrated that any weight loss achieved during hCG-based protocols is attributable to the severe calorie restriction that accompanies these programs, not to the hCG itself. Using Fertigyn HP for unapproved purposes exposes patients to unnecessary risks without established benefit.
Will fertigyn hp cause a false positive pregnancy test?
Yes, Fertigyn HP contains hCG, which is the same hormone detected by pregnancy tests. If a pregnancy test is performed within 7 to 10 days after a dose of hCG, it may show a positive result that reflects administered medication rather than a true pregnancy. For this reason, pregnancy testing after fertility treatment is usually scheduled at least 14 days after the hCG trigger shot to avoid false positive results.
Can i travel with fertigyn hp?
Fertigyn HP in its lyophilized form is stable at room temperature and can be transported without special refrigeration. Patients who need to travel while undergoing fertility treatment should plan accordingly, ensuring they have an adequate supply of medication, syringes, needles, and alcohol swabs for the duration of their trip. A letter from the healthcare provider explaining the medical necessity of the supplies can be helpful when going through airport security or customs.
How long does it take for sperm production to improve with hcg therapy?
In men with hypogonadotropic hypogonadism, sperm production typically begins to improve after 3 to 6 months of hCG therapy, although it may take longer in some patients. The timeline depends on several factors, including the severity and duration of gonadotropin deficiency, the presence of primary testicular dysfunction, and the specific dosing regimen used. Patience and persistence are important, as the process of spermatogenesis takes approximately 74 days from initiation to the release of mature sperm.